These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 12837348)

  • 21. Genotypic detection of fluoroquinolone resistance in drug-resistant Mycobacterium tuberculosis at a tertiary care centre in south Coastal Karnataka, India.
    Chawla K; Kumar A; Shenoy VP; Chakrabarty S; Satyamoorthy K
    J Glob Antimicrob Resist; 2018 Jun; 13():250-253. PubMed ID: 29421317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trial tests new combination of drugs to treat tuberculosis.
    Roehr B
    BMJ; 2012 Mar; 344():e2216. PubMed ID: 22434129
    [No Abstract]   [Full Text] [Related]  

  • 23. [Maxaquin in the combined treatment of tuberculosis].
    Sokolova GB; Mozhokina GN; Kunichan AD; Elistratova NA; Perel'man MI
    Probl Tuberk; 2000; (5):35-9. PubMed ID: 11077850
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Fluoroquinolones as antibacterial preparations and their use in the treatment of tuberculosis].
    Vishnevskaia EB; Kocherovets VI; Vishnevskiĭ BI
    Antibiot Khimioter; 2002; 47(6):42-7. PubMed ID: 12422649
    [No Abstract]   [Full Text] [Related]  

  • 25. [Prospects for development of new antituberculous drugs].
    Tomioka H
    Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistance.
    Gumbo T; Louie A; Deziel MR; Drusano GL
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3178-81. PubMed ID: 16048921
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.
    Sterling TR
    Int J Tuberc Lung Dis; 2004 Dec; 8(12):1396-400. PubMed ID: 15636484
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vitro, ex-vivo and in vivo activities of ethambutol and sparfloxacin alone and in combination against mycobacteria.
    Kaur D; Khuller GK
    Int J Antimicrob Agents; 2001 Jan; 17(1):51-5. PubMed ID: 11137649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolone resistance in multidrug-resistant
    Che Y; Song Q; Yang T; Ping G; Yu M
    Eur Respir J; 2017 Dec; 50(6):. PubMed ID: 29217603
    [No Abstract]   [Full Text] [Related]  

  • 30. In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.
    Bernard C; Aubry A; Chauffour A; Brossier F; Robert J; Veziris N
    J Antimicrob Chemother; 2016 Dec; 71(12):3465-3472. PubMed ID: 27605600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapid assays for fluoroquinolone resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis.
    Chang KC; Yew WW; Chan RC
    J Antimicrob Chemother; 2010 Aug; 65(8):1551-61. PubMed ID: 20542907
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Resistance to first- and second-line antituberculosis drugs in Southern Taiwan: Implications for empirical treatment.
    Kuo CY; Wang WH; Huang CH; Chen YH; Lu PL
    J Microbiol Immunol Infect; 2018 Feb; 51(1):88-93. PubMed ID: 28698044
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Molecular Genetics of Fluoroquinolone Resistance in Mycobacterium tuberculosis.
    Mayer C; Takiff H
    Microbiol Spectr; 2014 Aug; 2(4):MGM2-0009-2013. PubMed ID: 26104201
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fluoroquinolones: an important class of antibiotics against tuberculosis.
    De Souza MV; Vasconcelos TR; de Almeida MV; Cardoso SH
    Curr Med Chem; 2006; 13(4):455-63. PubMed ID: 16475933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fluoroquinolone consumption and -resistance trends in Mycobacterium tuberculosis and other respiratory pathogens: Ecological antibiotic pressure and consequences in Pakistan, 2009-2015.
    Shakoor S; Tahseen S; Jabeen K; Fatima R; Malik FR; Rizvi AH; Hasan R
    Int J Mycobacteriol; 2016 Dec; 5(4):412-416. PubMed ID: 27931682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In-vitro activity of fluorinated quinolones and macrolides against drug-resistant Mycobacterium tuberculosis.
    Hoffner SE; Gezelius L; Olsson-Liljequist B
    J Antimicrob Chemother; 1997 Dec; 40(6):885-8. PubMed ID: 9462443
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Additional drug resistance of multidrug-resistant tuberculosis in patients in 9 countries.
    Kurbatova EV; Dalton T; Ershova J; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Cegielski JP
    Emerg Infect Dis; 2015 Jun; 21(6):977-83. PubMed ID: 25988299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency and geographic distribution of gyrA and gyrB mutations associated with fluoroquinolone resistance in clinical Mycobacterium tuberculosis isolates: a systematic review.
    Avalos E; Catanzaro D; Catanzaro A; Ganiats T; Brodine S; Alcaraz J; Rodwell T
    PLoS One; 2015; 10(3):e0120470. PubMed ID: 25816236
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fluoroquinolone resistance in Mycobacterium tuberculosis isolates: associated genetic mutations and relationship to antimicrobial exposure.
    Wang JY; Lee LN; Lai HC; Wang SK; Jan IS; Yu CJ; Hsueh PR; Yang PC
    J Antimicrob Chemother; 2007 May; 59(5):860-5. PubMed ID: 17412727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Use of maxaquin in the treatment of progressive pulmonary tuberculosis occurring with standard chemotherapy regimens].
    Mar'iandyshev AO; Klinberg NM; Shonbina AI; Moroz MI
    Probl Tuberk; 1997; (4):19-21. PubMed ID: 9333808
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.